Cancer Genetics’ unique tissue of origin test (TOO®) receives special FDA 510(k) clearance
Cancer Genetics announced it has received special 510(k) clearance from the FDA for its Tissue of Origin test (TOO®) following modifications made to test reagents and software. TOO® is a microarray-based gene expression test that analyzes a tumor’s genomic information to help identify its origin. April 16, 2018
